The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.

Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

Using the Saxenda pen correctly is essential for safe and effective weight loss management. While the pen is designed to be user-friendly, many people make mistakes that can reduce its effectiveness ...

GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care. The ...

ANY SUBSTANTIAL CHANGE in your body weight, in either direction, will include a mix of fat and lean tissue. A steroid-free ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Another study suggests that weight-loss meds like Wegovy (NVO) and Mounjaro (LLY) can help people cut back on drinking ...

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change ...